Market Closed -
NSE India S.E.
12:43:55 28/06/2024 BST
|
5-day change
|
1st Jan Change
|
103.6
INR
|
+0.81%
|
|
-2.50%
|
+5.50%
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Capitalization
1 |
2,567
|
872.9
|
480.4
|
1,573
|
1,628
|
1,549
|
Enterprise Value (EV)
1 |
3,235
|
1,488
|
983.8
|
2,264
|
2,487
|
2,407
|
P/E ratio
|
12.9
x
|
-10.9
x
|
5.83
x
|
5.63
x
|
8.28
x
|
122
x
|
Yield
|
0.31%
|
-
|
-
|
-
|
-
|
-
|
Capitalization / Revenue
|
0.92
x
|
0.38
x
|
0.17
x
|
0.41
x
|
0.36
x
|
0.42
x
|
EV / Revenue
|
1.16
x
|
0.65
x
|
0.35
x
|
0.6
x
|
0.56
x
|
0.65
x
|
EV / EBITDA
|
6.9
x
|
15.5
x
|
4.35
x
|
4.34
x
|
5.65
x
|
9.99
x
|
EV / FCF
|
-66.4
x
|
13.6
x
|
5.05
x
|
-8.49
x
|
-10.4
x
|
-54.9
x
|
FCF Yield
|
-1.51%
|
7.33%
|
19.8%
|
-11.8%
|
-9.58%
|
-1.82%
|
Price to Book
|
2.44
x
|
0.91
x
|
0.46
x
|
1.2
x
|
1.08
x
|
1.02
x
|
Nbr of stocks (in thousands)
|
15,828
|
15,828
|
15,828
|
15,828
|
15,828
|
15,828
|
Reference price
2 |
162.2
|
55.15
|
30.35
|
99.40
|
102.8
|
97.85
|
Announcement Date
|
06/09/18
|
30/08/19
|
02/09/20
|
02/09/21
|
02/09/22
|
06/09/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net sales
1 |
2,794
|
2,276
|
2,824
|
3,801
|
4,476
|
3,702
|
EBITDA
1 |
468.7
|
95.76
|
226.1
|
521.9
|
440.6
|
241.1
|
EBIT
1 |
404.6
|
27.99
|
158.1
|
445.5
|
355
|
146.3
|
Operating Margin
|
14.48%
|
1.23%
|
5.6%
|
11.72%
|
7.93%
|
3.95%
|
Earnings before Tax (EBT)
1 |
293.5
|
-57.37
|
62.52
|
395.2
|
277.3
|
22.14
|
Net income
1 |
198.9
|
-80.31
|
82.52
|
279.7
|
196.6
|
12.7
|
Net margin
|
7.12%
|
-3.53%
|
2.92%
|
7.36%
|
4.39%
|
0.34%
|
EPS
2 |
12.57
|
-5.074
|
5.210
|
17.67
|
12.42
|
0.8000
|
Free Cash Flow
1 |
-48.71
|
109
|
194.9
|
-266.7
|
-238.3
|
-43.82
|
FCF margin
|
-1.74%
|
4.79%
|
6.9%
|
-7.02%
|
-5.32%
|
-1.18%
|
FCF Conversion (EBITDA)
|
-
|
113.83%
|
86.21%
|
-
|
-
|
-
|
FCF Conversion (Net income)
|
-
|
-
|
236.2%
|
-
|
-
|
-
|
Dividend per Share
2 |
0.5000
|
-
|
-
|
-
|
-
|
-
|
Announcement Date
|
06/09/18
|
30/08/19
|
02/09/20
|
02/09/21
|
02/09/22
|
06/09/23
|
Fiscal Period: March |
2018
|
2019
|
2020
|
2021
|
2022
|
2023
|
---|
Net Debt
1 |
668
|
615
|
503
|
691
|
859
|
859
|
Net Cash position
1 |
-
|
-
|
-
|
-
|
-
|
-
|
Leverage (Debt/EBITDA)
|
1.426
x
|
6.418
x
|
2.227
x
|
1.324
x
|
1.951
x
|
3.561
x
|
Free Cash Flow
1 |
-48.7
|
109
|
195
|
-267
|
-238
|
-43.8
|
ROE (net income / shareholders' equity)
|
20.8%
|
-8.05%
|
8.27%
|
23.8%
|
14%
|
0.84%
|
ROA (Net income/ Total Assets)
|
11.9%
|
0.8%
|
4.47%
|
11.3%
|
7.49%
|
2.66%
|
Assets
1 |
1,673
|
-10,007
|
1,846
|
2,479
|
2,625
|
477.7
|
Book Value Per Share
2 |
66.50
|
60.50
|
65.70
|
82.70
|
95.10
|
96.00
|
Cash Flow per Share
2 |
0.2700
|
0.9100
|
1.030
|
0.3700
|
1.230
|
1.700
|
Capex
1 |
160
|
66.9
|
69.3
|
314
|
277
|
279
|
Capex / Sales
|
5.73%
|
2.94%
|
2.46%
|
8.27%
|
6.18%
|
7.54%
|
Announcement Date
|
06/09/18
|
30/08/19
|
02/09/20
|
02/09/21
|
02/09/22
|
06/09/23
|
|
1st Jan change
|
Capi.
|
---|
| +20.76% | 43.59B | | +28.00% | 22.54B | | +20.44% | 15.73B | | +18.82% | 14.33B | | +55.83% | 12.75B | | -0.05% | 6.79B | | -12.70% | 6.48B | | -8.87% | 5.73B | | +15.72% | 5.67B |
Generic Pharmaceuticals
|